ServiceNow (NOW) stock rises as Jan. 28 earnings date set — key levels and risks to watch
8 January 2026
1 min read

ServiceNow (NOW) stock rises as Jan. 28 earnings date set — key levels and risks to watch

New York, January 7, 2026, 21:28 EST — Market closed

  • ServiceNow shares ended up 1.4% at $150.90 on Wednesday, extending a three-day run of gains.
  • The company will report fourth-quarter and full-year 2025 results after the close on Jan. 28.
  • The stock is still well below its recent highs, with traders watching macro data and rates into late January.

ServiceNow (NOW) shares rose 1.4% to $150.90 on Wednesday, their third straight gain, even as the broader market slipped. Trading volume was about 6 million shares, below its 50-day average, market data showed. The company said it will release fourth-quarter and full-year 2025 results after the close on Jan. 28 and hold a conference call at 2 p.m. Pacific. 1

That date lands with the stock pinned near the lower end of its 52-week range. ServiceNow is below its 50-day moving average of $166.28 and its 200-day average of $181.17 — a moving average is simply an average price over a set period — with the 52-week low at $135.73. 2

Investors are also waiting to hear more about ServiceNow’s agreement to buy cybersecurity firm Armis for about $7.75 billion in cash, which the company expects to fund with cash on hand and debt and close in the second half of 2026. CFO Gina Mastantuono told Reuters at the time the company’s security stack was “very well positioned” and it would not need more security M&A — shorthand for mergers and acquisitions — in that space. 3

Macro could intrude before ServiceNow reports. The U.S. employment report is due at 8:30 a.m. ET on Friday, the consumer price index is scheduled for Jan. 13, and the Federal Reserve’s next policy meeting runs Jan. 27-28. 4

For ServiceNow, the January call will hinge on the 2026 outlook for subscription revenue — the recurring sales tied to software subscriptions — and whether large customers keep signing multi-year deals. Any update on Armis integration costs and the financing plan will get picked over.

ServiceNow sits in the same trade as other big U.S. business-software names such as Salesforce, and its valuation multiple — what investors pay for earnings — can make it sensitive to rate swings. A hotter inflation print tends to pinch that group.

But the setup cuts both ways. If late-January guidance looks cautious, or if customers stretch out renewals and upgrades, subscription growth can cool quickly and the stock has little technical support until the mid-$130s.

Markets reopen Thursday with NOW still far below last year’s high, and with a stack of macro prints ahead. The next hard marker for ServiceNow stock is the Jan. 28 earnings report after the close.

Stock Market Today

MARA stock jumps 22% into weekend as bitcoin whipsaws; Monday risk test looms

MARA stock jumps 22% into weekend as bitcoin whipsaws; Monday risk test looms

7 February 2026
MARA shares jumped 22.4% to $8.24 Friday, trading higher after hours, as the company moved $87 million in bitcoin to major custodians. About 82.4 million MARA shares changed hands. Bitcoin hovered near $68,928 Saturday. A MARA filing showed its general counsel had shares withheld for taxes on vested stock units, not an open market sale.
Apple stock (AAPL) set for Monday test as memory-chip crunch revives iPhone price question

Apple stock (AAPL) set for Monday test as memory-chip crunch revives iPhone price question

7 February 2026
Apple shares closed up 0.8% at $278.12 Friday, then slipped 0.3% after hours. A global DRAM shortage is raising component costs, putting pressure on Apple’s pricing ahead of its Feb. 24 shareholder meeting. CEO Tim Cook said memory prices will rise “sharply” but gave no details on possible iPhone price hikes. Investors await signals before next week’s U.S. inflation data.
Roivant stock surges on brepocitinib skin-disease data; what to watch into Monday

Roivant stock surges on brepocitinib skin-disease data; what to watch into Monday

7 February 2026
Roivant shares surged 22.4% to $25.82 after Phase 2 data showed its drug brepocitinib outperformed placebo in cutaneous sarcoidosis, with no serious adverse events. The company plans a Phase 3 trial in 2026 and has filed for FDA approval in dermatomyositis. Quarterly revenue reached $2 million, with a $313.7 million loss. Cash holdings stood at $4.5 billion.
Danaher stock slips as analysts lift targets ahead of JPM Healthcare Conference, earnings
Previous Story

Danaher stock slips as analysts lift targets ahead of JPM Healthcare Conference, earnings

DBS Smashes S$58, OCBC Tops S$20: Singapore Bank Stocks Hit Records as Dividend Hunt Intensifies
Next Story

DBS Smashes S$58, OCBC Tops S$20: Singapore Bank Stocks Hit Records as Dividend Hunt Intensifies

Go toTop